Esperite : (ESP) and BGI Genomics (BGI) sign a strategic agreement to offer Whole Genome Sequencing on a large scale.

Esperite with BGI sequencing technology will enable the global population easier access to the gold standard in clinical genetic testing.

Amsterdam, The Netherlands - 31 January 2018

BGI is the world's genome sequencing center. Esperite's new partner will provide the infrastructure and the technology for massive sequencing of the Whole Genome. BGI has also processed over 10 million clinical samples, including running 2.8 million noninvasive prenatal tests, 2.6 million human papillomavirus tests, 1.5 million hearing impairment tests.

Esperite's companies have developed a specific bioinformatics pipeline and will offer this premium diagnostic solution to patients through their international network of more than 6,000 Doctors, Hospitals and Clinics across Europe, EMEA and Asia.

BGI has accepted to finance Esperite's access to the technology. In return Esperite issued a convertible noted in favor of BGI for an amount of 520'000 Euros, maturity 12 months and interest rate 1%. BGI and Esperite can decide on conversion at anytime for a price of 0,78 Euro.

Whole genome sequencing (also known as WGS) is the process of determining the complete DNA sequence of an organism's genome during at a sophisticated single analysis.

WGS is the Gold Standard for Genetic Diagnostic and is the way of personalized medicine. WGS replaces all the other technologies on the market. It is extensive, accurate, and constitutes the foundation of a strategy of Big Data Mining and Health management.

To date, diagnostic tests were limited in practice to avoid the cost of large sequencing processes; PCR and Targeted Sequencing focus to analyse limited segment(s) of the Genome.

Combined with continuous discoveries and better understanding of genes and diseases as data is processed together with data driven medicine, whole genome sequencing already is and will continue on a larger scale to change current clinical practice by enabling more accurate and sophisticated genetic analysis.

BGI has the capacity to handle the very large anticipated amount of tests for this project  and will perform the sequencing of the samples with its state of the art NGS technology.
Esperite is confident that its technology, validated on thousands of samples is appropriate to offer Precision Medicine at a low entry cost for the entire population. In principle it constitutes a powerful screening tools and an accurate and universal diagnostic test.

Once the Genome of a patient is entirely decoded and converted in a personal and confidential file with a size of roughly 80 GigaBytes, Clinical analysis can be performed on demand by using the technology of Esperite.

Sequencing whole genome helps people to improve their health by giving relevant insights into family history, lifestyle and allows to understand inherited diseases risks. Learning if they are a carrier of a genetic condition and what they could pass on to their children is information of most importance.

Frederic Amar: "Esperite provides accessible and affordable genetic information towards a proactive approach to health leading transformative research and translating it into tangible benefits for society.
This method using Next Generation Sequencing (NGS) technology produces large volumes of data in a short amount of time and therefore is designed to empower healthcare professionals and patients with quality sequencing data at fast turnaround times.
Fifteen years ago, a Whole Genome cost was close to One Million Euro. We will offer it for less than a Thousand Euro."

About ESPERITE

ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com or visit the websites at www.esperite.com,  www.genoma.com and www.cryo-save.com.

***

This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).

With respect to Member States of the European Economic Area that have transposed European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State.
This press release and the information it contains do not, and will not, constitute an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, securities of Esperite in the United States of America or any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), it being specified that the securities of Esperite have not been and will not be registered within the US Securities Act. Esperite does not intend to register securities or conduct a public offering in the United States of America.